


CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the
U.S. Patent and Trademark Office on the date shown below.

Theresa M. Munro

Type Name of Person faxing this document

October 5, 2006

Signature

Date

Attorney Docket No. P31220X2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard, et al. October 5, 2006
Serial No.: 10/024,858 Group Art Unit No.: 1615
Filed: December 18, 2001 Examiner: Humera Sheikh
For: "PAROXETINE CONTROLLED RELEASE COMPOSITIONS"

FAX RECEIVED**OCT 05 2006****OFFICE OF PETITIONS**

Commissioner for Patents
BOX RCE
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except for those documents which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

This application was allowed at the time of filing an RCE concurrent with this IDS. The corresponding European application granted as European patent No. EP 0 839 039 B1, on November 5, 2003. On August 4 and on August 5, 2004 oppositions were filed in the matter of European patent No. EP 0 839 039 B1.

This Information Disclosure Statement contains an opposition paper dated August 4, 2006, and 2 references cited in the opposition paper that are not already part of the filewrapper. Other references referred to in the opposition paper are indicated in the table below.

- 2 -

Serial No.: 10/024,858
Group Art Unit No.: 1615

Number	Document	Filewrapper
D1	Aulton Ed. "Pharmaceutics: The Science Of Dosage from Design", pp. 204-211, Churchill Livingstone, Edinburgh (1988)	IDS filed September 2, 2004 Reference CI
D2	EP-A-0269303	IDS filed March 12, 2002 Reference BE
D4/D3a	US 5,102,666	IDS filed October 18, 2001 Reference AA
D5	WO 92/09281	IDS filed March 12, 2002 Reference BD
D24	WO 95/15155	IDS filed October 18, 2001 Reference BA
D28	US 4,851,228	IDS filed September 2, 2004 Reference AH
D29	WO 93/24154	IDS filed September 2, 2004 Reference BI
D30	EP-A-654263	IDS filed September 2, 2004 Reference BJ
D31	Perucca, et al. Clin. Pharm., 1994, 27(3): pp. 175-190	IDS filed September 2, 2004 Reference CZ
D32	ABPI Data sheet Compendium 1988-89 pp. 445-446	IDS filed September 2, 2004 Reference CAA
D33	Freeman, J. Psychiatry Neuroscience Vol. 16, No. 2, (Supp 1), 1991.	IDS filed September 2, 2004 Reference CAB

This Information Disclosure Statement is intended to alert the United States Patent and Trademark Office to the status of an ongoing opposition in the corresponding European patent. Applicants contend that the currently pending claims are allowable over the enclosed documents.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to contact the undersigned attorney at the number indicated below.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090

N:\wjd\paroxetine\P31220 Paxil CR\IDS letter for withdraw#2.doc

Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Leonard, et al.	FAX RECEIVED OCT 05 2006 OFFICE OF PETITIONS
		FILING DATE December 18, 2001	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,151,434	09/29/1992	Irikura, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Opposition to European Patent No. EP-B-0839039 dated 04 August 2006.
	Lee & Robinson, 1978, Chapter 3 "Methods to achieve sustained drug delivery". pp. 150 and 176-178.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\wjd\paroxetine\p31220 paxil cr\pto 1449 form with withdraw #2.doc